RxDoctor Payments Data

David Sternheim, MD

Cardiovascular Disease · Yonkers, NYNPI 1841680519

Payments from drug & device makers

$418in general payments, 2019–2025

Across 13 payments — averaging $32.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$100
  • Astellas Pharma US Inc$89
  • Philips North America LLC$47
  • Boston Scientific$46
  • Novartis$41
  • Lantheus Medical Imaging, Inc.$24
  • plus $71 from 4 others

What the payments were for

  • Food & beverage$31475%
  • Education$10425%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$418 in reported general payments places this provider in the 25th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$468,861
Medicare patients
2,022
Services billed
5,821

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban430$557,686
VyndamaxTafamidis13$325,534
EntrestoSacubitril/Valsartan167$221,702
JardianceEmpagliflozin135$162,148
XareltoRivaroxaban83$116,481
Repatha SureclickEvolocumab88$62,045
FarxigaDapagliflozin Propanediol26$32,392
Atorvastatin Calcium612$9,529
Metoprolol Succinate610$8,980
Rosuvastatin Calcium382$7,616
Ezetimibe203$6,298
Ranolazine ErRanolazine24$5,222
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide128$3,898
Eplerenone46$3,383
Amiodarone Hcl16$3,153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$19$883,221443 claims
NovartisEntresto$41$221,702167 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Yonkers

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →